Related Experiment Videos
[Chronic hepatitis C drug therapy update]
R Ruano Camps1, C Gallego Fernández
1Servicio de Farmacia. Hospital General Carlos Haya. Málaga. Spain.
Summary
Hepatitis C Virus (HCV) treatment has improved, with newer therapies achieving 55% sustained viral response (SVR). However, these advanced treatments significantly increase pharmaceutical costs, necessitating careful management within hospital drug policies.
Area of Science:
- Hepatology
- Virology
- Pharmacoeconomics
Context:
- Chronic Hepatitis C Virus (HCV) infection presents significant global health and economic challenges.
- Current treatment aims for sustained viral response (SVR), signifying disease cure.
Purpose:
- To review the advancements in Hepatitis C Virus (HCV) treatment efficacy and associated financial implications.
- To emphasize the need for rational drug use policies and established protocols for managing novel HCV therapies.
Summary:
- Therapeutic efficacy for chronic hepatitis C has advanced from 15% SVR with interferon monotherapy to 55% SVR with pegylated interferons and ribavirin.
- Patient stratification by genotyping and viral load influences treatment outcomes.
- These improved outcomes are linked to substantial increases in pharmaceutical expenditure.
Impact:
- The rising cost of effective HCV treatments necessitates their inclusion in hospital pharmacotherapeutic guides.
- Development of clear usage criteria and therapeutic protocols is crucial for rational drug use and cost containment.
- Effective pharmacotherapeutic monitoring is essential for optimizing patient outcomes and managing healthcare resources.